Eutillio Buccilli - Genetic Technologies CEO
| GENE Stock | USD 2.39 0.02 0.84% |
CEO
Mr. Eutillio Buccilli is Chief Executive Officer of Genetic Technologies Limited. He was appointed to the position of Executive Director of the Company with effect from 12 June 2015. Mr. Buccilli joined the Company in June 2014 as Chief Financial Officer. In November 2014, Mr. Buccilli was appointed to the position of Chief Operating Officer and Chief Financial Officer and was subsequently appointed Chief Executive Officer in February 2015. Mr. Buccilli has more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with blue chip corporations such as General Electric, Computer Science Corporationrationration, Coles Myer and Challenger Limited. Whilst at GE, Mr. Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut. since 2018.
| Age | 63 |
| Tenure | 6 years |
| Address | 60-66 Hanover Street, Fitzroy, VIC, Australia, 3065 |
| Phone | 61 3 8412 7000 |
| Web | https://genetype.com |
Genetic Technologies Management Efficiency
The company has return on total asset (ROA) of (0.5271) % which means that it has lost $0.5271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6047) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -1.26. In addition to that, Return On Capital Employed is expected to decline to -1.04. At present, Genetic Technologies' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Total Current Assets are forecasted to decline to about 11.7 M.Similar Executives
| Found 6 records | CEO Age | ||
| Adrian Gottschalk | Foghorn TherapeuticsInc | 48 | |
| Aaron Gravitz | Shattuck LabsInc | 34 | |
| PharmD MBA | Century Therapeutics | N/A | |
| Lynn MD | Lyell Immunopharma | 65 | |
| David Hung | Nuvation Bio | 63 | |
| Markus MD | Monte Rosa Therapeutics | 52 | |
Management Performance
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 |
Genetic Technologies Leadership Team
Elected by the shareholders, the Genetic Technologies' board of directors comprises two types of representatives: Genetic Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genetic. The board's role is to monitor Genetic Technologies' management team and ensure that shareholders' interests are well served. Genetic Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genetic Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Grahame Leonard, Director | ||
| Paul Viney, CFO, COO, Company Secretary | ||
| Mark Ostrowski, President of Phenogen Sciences Inc. | ||
| Diana Newport, Quality and Bus. Operations Director | ||
| CPA BCom, Chief Secretary | ||
| AGIA BCom, CFO Sec | ||
| Bus FCI, Consultant | ||
| Peter Rubenstein, Director | ||
| Justyn Stedwell, Company Secretary | ||
| Susan Gross, Senior Medical Director | ||
| Paul Kasian, Non-Executive Director | ||
| Bronwyn Christie, | ||
| Kevin Camilleri, Chief EasyDNA | ||
| Phillip Hains, CFO | ||
| Malcolm Brandon, Non-Executive Chairman of the Board | ||
| Eutillio Buccilli, CEO, Executive Director and Member of Remuneration Committee | ||
| Luisa Ashdown, Director of Global Licensing and Intellectual Property | ||
| Kevin Fischer, CFO | ||
| Lindsay Wakefield, Non-Executive Independent Director | ||
| Jerzy Muchnicki, Director | ||
| Xue Lee, Director | ||
| Simon Morriss, Chief Officer | ||
| Richard Allman, Scientific Director | ||
| Carl BSc, Chief Officer |
Genetic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genetic Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 270.19 M | ||||
| Shares Outstanding | 4.41 M | ||||
| Shares Owned By Institutions | 0.56 % | ||||
| Number Of Shares Shorted | 11.53 K | ||||
| Price To Earning | (1.87) X | ||||
| Price To Book | 4.08 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Genetic Stock analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 2.73 | Quarterly Revenue Growth (0.02) | Return On Assets (0.53) | Return On Equity (1.60) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.